Page 304 - Haematologica May 2020
P. 304

A. Radujkovic et al.
Asymmetric dimethylarginine serum levels
are associated with early mortality after allogeneic stem cell transplantation. Haematologica. 2019;104(4):827-834.
5. Lindås R, Tvedt TH, Hatfield KJ, Reikvam H, Bruserud O. Preconditioning serum lev- els of endothelial cell-derived molecules and the risk of posttransplant complica- tions in patients treated with allogeneic stem cell transplantation. J Transplant. 2014;2014:404096.
6. Tatekawa S, Kohno A, Ozeki K, et al. A Novel Diagnostic and Prognostic Biomarker Panel for Endothelial Cell Damage-Related Complications in Allogeneic Transplantation. Biol Blood Marrow Transplant. 2016;22(9):1573-1581.
7. Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007;30(11):1029- 1034.
8. Empen K, Lorbeer R, Dörr M, et al. Association of testosterone levels with endothelial function in men: results from a population-based study. Arterioscler Thromb Vasc Biol. 2012;32(2):481-486.
9. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analy- sis. J Clin Endocrinol Metab. 2011;96(10):3007-3019.
10. Hollard D, Sotto JJ, Berthier R, Leger J, Michallet M. High rate of long-term sur- vivals in AML treated by chemotherapy and androgenotherapy: a pilot study. Cancer. 1980;45(7):1540-1548.
11. Hayat M, Jehn U, Willemze R, et al. A ran- domized comparison of maintenance treat- ment with androgens, immunotherapy, and chemotherapy in adult acute myeloge- nous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC. Cancer. 1986;58(3):617-623.
12. Pigneux A, Béné MC, Guardiola P, et al. Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study. J Clin Oncol. 2017;35(4):387-393.
13. Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009; 115(20):4715-4726.
14. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
15. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660-1605.
16. Haring R, Völzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a popu- lation-based cohort of men aged 20-79. Eur Heart J. 2010;31(12):1494-1501.
17. Björk Y, Smith Knutsson E, Ankarberg- Lindgren C, et al. Androgens in women after allogeneic hematopoietic cell trans- plantation: impact of chronic GvHD and glucocorticoid therapy. Bone Marrow Transplant. 2017;52(3):431-437.
18. Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone mar- row transplant survivors receiving busul- fan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant. 2000;26(10):1089- 1095.
19. Tauchmanovà L, Selleri C, De Rosa G, et al. Gonadal status in reproductive age women after haematopoietic stem cell transplanta- tion for haematological malignancies. Hum Reprod. 2003;18(7):1410-1416.
20. dos Santos RL, da Silva FB, Ribeiro RF Jr, Stefanon I. Sex hormones in the cardiovas- cular system. Horm Mol Biol Clin Investig. 2014;18(2):89-103.
21. Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001;7(4):363-369.
22. Zhang J, Ye J, Ma D, et al. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Carcinogenesis. 2013;34(3):667-677.
23. Cogle CR, Goldman DC, Madlambayan GJ, et al. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia. 2014;28(10):1978-1987.
24. Hatfield K, Øyan AM, Ersvaer E, et al. Primary human acute myeloid leukaemia cells increase the proliferation of microvas- cular endothelial cells through the release of soluble mediators. Br J Haematol. 2009; 144(1):53-68.
25. Reikvam H, Hatfield KJ, Fredly H, Nepstad I, Mosevoll KA, Bruserud Ø. The angioreg- ulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell trans- plantation. Eur Cytokine Netw. 2012; 23(4):140-153.
26. Afferni C, Buccione C, Andreone S, et al. The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. Front Immunol. 2018; 9:2601.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Andersson C, Enserro D, Sullivan L, et al. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. Atherosclerosis. 2016;248:245-251.
Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY. Angiopoietin-2 levels as a biomark- er of cardiovascular risk in patients with hypertension. Ann Med. 2008;40(3):215- 222.
Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resis- tant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.
Gencer B, Mach F. Testosterone: a hormone preventing cardiovascular disease or a ther- apy increasing cardiovascular events? Eur Heart J. 2016;37(48):3569-3575.
Snyder PJ, Ellenberg SS, Cunningham GR, et al. The Testosterone Trials: Seven coordi- nated trials of testosterone treatment in elderly men. Clin Trials. 2014;11(3):362- 375.
Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017;317(7):708- 716.
Blagosklonny MV, Neckers LM. Cytostatic and cytotoxic activity of sex steroids against human leukemia cell lines. Cancer Lett. 1994;76(2-3):81-86.
Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hor- monal milieu in men. J Clin Endocrinol Metab. 1992;74(4):939-942.
Huo S, Scialli AR, McGarvey S, et al. Treatment of Men for "Low Testosterone": A Systematic Review. PLoS One. 2016;11(9):e0162480.
Grech A, Breck J, Heidelbaugh J. Adverse effects of testosterone replacement thera- py: an update on the evidence and contro- versy. Ther Adv Drug Saf. 2014;5(5):190- 200.
Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628- 1633.
Bornhäuser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13(10):1035-1044.
    1464
  haematologica | 2020; 105(5)
   















































   302   303   304   305   306